vs
BillionToOne, Inc.（BLLN）与CENTERSPACE（CSR）财务数据对比。点击上方公司名可切换其他公司
BillionToOne, Inc.的季度营收约是CENTERSPACE的1.3倍（$83.5M vs $65.1M），BillionToOne, Inc.净利率更高（6.8% vs -23.0%，领先29.8%），BillionToOne, Inc.同比增速更快（117.4% vs -3.0%）
BillionToOne, Inc.是一家生命科学与分子诊断企业，专注研发高精度基因检测解决方案，核心产品包括无创产前检测、肿瘤诊断试剂及罕见病筛查服务，服务全球多地的医疗机构、患者及科研合作方。
Centerspace是一家专注于多户住宅物业持有、运营与开发的房地产投资企业，核心业务覆盖美国中西部及落基山西部区域，面向不同租户群体提供经济型及高端住宅选择，重视租户体验与资产长期价值增长。
BLLN vs CSR — 直观对比
营收规模更大
BLLN
是对方的1.3倍
$65.1M
营收增速更快
BLLN
高出120.4%
-3.0%
净利率更高
BLLN
高出29.8%
-23.0%
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $83.5M | $65.1M |
| 净利润 | $5.7M | $-15.0M |
| 毛利率 | 69.9% | — |
| 营业利润率 | 11.5% | — |
| 净利率 | 6.8% | -23.0% |
| 营收同比 | 117.4% | -3.0% |
| 净利润同比 | 138.3% | -258.1% |
| 每股收益（稀释后） | $0.10 | $-0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLLNCSR
| Q1 26 | — | $65.1M | ||
| Q4 25 | — | $66.6M | ||
| Q3 25 | $83.5M | $71.4M | ||
| Q2 25 | — | $68.5M | ||
| Q1 25 | — | $67.1M | ||
| Q4 24 | $45.1M | $66.4M | ||
| Q3 24 | $38.4M | $65.0M | ||
| Q2 24 | — | $65.0M |
净利润BLLNCSR
| Q1 26 | — | $-15.0M | ||
| Q4 25 | — | $-18.4M | ||
| Q3 25 | $5.7M | $53.8M | ||
| Q2 25 | — | $-14.5M | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | $-11.5M | $-5.1M | ||
| Q3 24 | $-14.9M | $-1.0M | ||
| Q2 24 | — | $-1.3M |
毛利率BLLNCSR
| Q1 26 | — | — | ||
| Q4 25 | — | 96.5% | ||
| Q3 25 | 69.9% | 96.5% | ||
| Q2 25 | — | 96.5% | ||
| Q1 25 | — | 96.4% | ||
| Q4 24 | 57.1% | 96.5% | ||
| Q3 24 | 52.6% | 96.6% | ||
| Q2 24 | — | 96.6% |
营业利润率BLLNCSR
| Q1 26 | — | — | ||
| Q4 25 | — | -15.9% | ||
| Q3 25 | 11.5% | — | ||
| Q2 25 | — | -9.9% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | 17.0% | 4.3% | ||
| Q3 24 | -32.9% | 9.8% | ||
| Q2 24 | — | 11.1% |
净利率BLLNCSR
| Q1 26 | — | -23.0% | ||
| Q4 25 | — | -27.7% | ||
| Q3 25 | 6.8% | 75.3% | ||
| Q2 25 | — | -21.2% | ||
| Q1 25 | — | -5.6% | ||
| Q4 24 | -25.5% | -7.6% | ||
| Q3 24 | -38.8% | -1.6% | ||
| Q2 24 | — | -2.0% |
每股收益（稀释后）BLLNCSR
| Q1 26 | — | $-0.49 | ||
| Q4 25 | — | $-1.08 | ||
| Q3 25 | $0.10 | $3.19 | ||
| Q2 25 | — | $-0.87 | ||
| Q1 25 | — | $-0.22 | ||
| Q4 24 | $-1.13 | $-0.31 | ||
| Q3 24 | $-1.47 | $-0.40 | ||
| Q2 24 | — | $-0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.2M | $7.6M |
| 总债务越低越好 | $55.0M | — |
| 股东权益账面价值 | $-239.5M | $695.0M |
| 总资产 | $327.5M | $1.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BLLNCSR
| Q1 26 | — | $7.6M | ||
| Q4 25 | — | $12.8M | ||
| Q3 25 | $195.2M | $12.9M | ||
| Q2 25 | — | $12.4M | ||
| Q1 25 | — | $11.9M | ||
| Q4 24 | $191.5M | $12.0M | ||
| Q3 24 | — | $14.5M | ||
| Q2 24 | — | $14.3M |
总债务BLLNCSR
| Q1 26 | — | — | ||
| Q4 25 | — | $1.0B | ||
| Q3 25 | $55.0M | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $955.5M | ||
| Q4 24 | $51.5M | $955.4M | ||
| Q3 24 | — | $921.3M | ||
| Q2 24 | — | $931.7M |
股东权益BLLNCSR
| Q1 26 | — | $695.0M | ||
| Q4 25 | — | $719.2M | ||
| Q3 25 | $-239.5M | $748.6M | ||
| Q2 25 | — | $710.1M | ||
| Q1 25 | — | $636.8M | ||
| Q4 24 | $-251.7M | $752.0M | ||
| Q3 24 | $-242.9M | $672.5M | ||
| Q2 24 | — | $680.7M |
总资产BLLNCSR
| Q1 26 | — | $1.9B | ||
| Q4 25 | — | $1.9B | ||
| Q3 25 | $327.5M | $2.1B | ||
| Q2 25 | — | $2.0B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | $302.1M | $1.9B | ||
| Q3 24 | — | $1.9B | ||
| Q2 24 | — | $1.9B |
负债/权益比BLLNCSR
| Q1 26 | — | — | ||
| Q4 25 | — | 1.42× | ||
| Q3 25 | — | 1.53× | ||
| Q2 25 | — | 1.57× | ||
| Q1 25 | — | 1.50× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | — | 1.37× | ||
| Q2 24 | — | 1.37× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.8M | — |
| 自由现金流经营现金流 - 资本支出 | $6.5M | — |
| 自由现金流率自由现金流/营收 | 7.7% | — |
| 资本支出强度资本支出/营收 | 8.8% | 0.3% |
| 现金转化率经营现金流/净利润 | 2.42× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BLLNCSR
| Q1 26 | — | — | ||
| Q4 25 | — | $98.5M | ||
| Q3 25 | $13.8M | $35.1M | ||
| Q2 25 | — | $25.3M | ||
| Q1 25 | — | $25.4M | ||
| Q4 24 | — | $98.2M | ||
| Q3 24 | — | $32.3M | ||
| Q2 24 | — | $22.9M |
自由现金流BLLNCSR
| Q1 26 | — | — | ||
| Q4 25 | — | $64.3M | ||
| Q3 25 | $6.5M | $25.7M | ||
| Q2 25 | — | $15.5M | ||
| Q1 25 | — | $20.4M | ||
| Q4 24 | — | $41.6M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $9.1M |
自由现金流率BLLNCSR
| Q1 26 | — | — | ||
| Q4 25 | — | 96.5% | ||
| Q3 25 | 7.7% | 36.0% | ||
| Q2 25 | — | 22.7% | ||
| Q1 25 | — | 30.4% | ||
| Q4 24 | — | 62.6% | ||
| Q3 24 | — | 31.5% | ||
| Q2 24 | — | 14.0% |
资本支出强度BLLNCSR
| Q1 26 | — | 0.3% | ||
| Q4 25 | — | 51.3% | ||
| Q3 25 | 8.8% | 13.1% | ||
| Q2 25 | — | 14.2% | ||
| Q1 25 | — | 7.5% | ||
| Q4 24 | — | 85.3% | ||
| Q3 24 | — | 18.2% | ||
| Q2 24 | — | 21.2% |
现金转化率BLLNCSR
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
CSR
暂无分部数据
